CardiolRx (cannabidiol) / Cardiol Therap - LARVOL DELTA

Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis (clinicaltrials.gov) - P2 | N=109 | Completed | Sponsor: Cardiol Therapeutics Inc. | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Inflammation

MAVERIC-2: CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation (clinicaltrials.gov) - P3 | N=110 | Not yet recruiting | Sponsor: Cardiol Therapeutics Inc. | Phase classification: P2/3 ➔ P3

Phase classification • Cardiovascular

Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis (clinicaltrials.gov) - P2 | N=109 | Active, not recruiting | Sponsor: Cardiol Therapeutics Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Nov 2024 ➔ Jan 2025

Enrollment closed • Trial primary completion date • Cardiovascular • Inflammation • IL10 • IL1B • IL6 • TNFA

MAVERIC-2: CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation (clinicaltrials.gov) - P2/3 | N=110 | Not yet recruiting | Sponsor: Cardiol Therapeutics Inc.

New P2/3 trial • Cardiovascular

Pharmaceutically Manufactured Cannabidiol Demonstrates Clinically Relevant Reductions in Pericarditis Pain and C-Reactive Protein in Patients with Recurrent Pericarditis – the MAvERIC-Pilot Study (AHA 2024) - "Pts had to be on chronic treatment with NSAIDs, colchicine or corticosteroids (any combination) with stable baseline (BL) doses... Among pts with symptomatic pericarditis recurrence, oral administration of P-cannabidiol led to a clinically relevant reduction in pericarditis chest pain (measured by NRS score) and in CRP. P-cannabidiol was shown to be safe and generally well tolerated, with the majority of pts reaching the target dose and continuing into the study EP."

Clinical • Cardiovascular • Pain • CRP • IL1B • IL6 • NLRP3

Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot) (clinicaltrials.gov) - P2 | N=25 | Completed | Sponsor: Cardiol Therapeutics Inc. | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • CRP

Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot) (clinicaltrials.gov) - P2 | N=25 | Active, not recruiting | Sponsor: Cardiol Therapeutics Inc. | Trial completion date: Dec 2024 ➔ Sep 2024 | Trial primary completion date: Nov 2024 ➔ Jun 2024

Trial completion date • Trial primary completion date • Cardiovascular • CRP

Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot) (clinicaltrials.gov) - P2 | N=25 | Active, not recruiting | Sponsor: Cardiol Therapeutics Inc. | Trial completion date: Sep 2024 ➔ Dec 2024 | Trial primary completion date: Jun 2024 ➔ Nov 2024

Trial completion date • Trial primary completion date • Cardiovascular • CRP

Impact of CardiolRxTM on Myocardial Recovery in Patients with Acute MyocarditisA double-blind, placebo-controlled trial (clinicaltrialsregister.eu) - P2 | N=100 | Sponsor: Cardiol Therapeutics Inc.

New P2 trial • Cardiovascular • Inflammation • IL10 • IL18 • IL1B • IL6 • TGFB1 • TNFA • VCAM1

Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: Rationale & design of the ARCHER trial. (PubMed, ESC Heart Fail) - "The ongoing ARCHER Trial is an international, multicentre, double-blind, randomized, placebo-controlled phase II study, designed to determine the effect of a pharmaceutically produced cannabidiol formulation on CMR parameters in patients presenting with acute myocarditis. Enrolment of 100 patients is expected to conclude in Q3 2024. Study results will be available in early 2025."

Journal • Cardiovascular • CNS Disorders • Congestive Heart Failure • Heart Failure • Immunology • Inflammation • Rare Diseases • Transplantation

Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: initial characteristics of the population, design and rationale of the ARCHER trial (HEART FAILURE 2024) - "The ongoing ARCHER Trial is an international randomised phase II study, designed to demonstrate a potential effect of a pharmaceutically produced cannabidiol formulation on CMR parameters and will enrol 100 patients presenting with acute myocarditis."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot) (clinicaltrials.gov) - P2 | N=25 | Active, not recruiting | Sponsor: Cardiol Therapeutics Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Mar 2024 ➔ Jun 2024

Enrollment closed • Trial primary completion date • Cardiovascular • CRP

Impact of CardiolRxTM on Recurrent Pericarditis (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: Cardiol Therapeutics Inc.

Trial completion date • Trial primary completion date • Cardiovascular • CRP

Impact of CardiolRx on Myocardial Recovery in Acute Myocarditis (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Cardiol Therapeutics Inc. | Trial completion date: Jun 2025 ➔ Dec 2024

Trial completion date • Cardiovascular • Inflammation

Impact of CardiolRxTM on Recurrent Pericarditis (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: Cardiol Therapeutics Inc. | Trial primary completion date: Jun 2024 ➔ Mar 2024

Trial primary completion date • Cardiovascular • CRP

Impact of CardiolRxTM on Recurrent Pericarditis (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: Cardiol Therapeutics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Pain • CRP

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors (clinicaltrials.gov) - P2/3 | N=90 | Terminated | Sponsor: Cardiol Therapeutics Inc. | N=422 ➔ 90 | Trial completion date: Aug 2023 ➔ Nov 2022 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2023 ➔ Nov 2022; The changing nature of COVID-19 including a more vaccinated population, increasing natural population immunity, milder variants and other related factors has meant that it is no longer realistic to recruit the patients in a reasonable time frame.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Cardiovascular • Infectious Disease • Novel Coronavirus Disease

Impact of CardiolRxTM on Recurrent Pericarditis (clinicaltrials.gov) - P2 | N=25 | Not yet recruiting | Sponsor: Cardiol Therapeutics Inc. | Phase classification: P1 ➔ P2

Phase classification • Cardiovascular • Pain • CRP

Impact of CardiolRx on Myocardial Recovery in Acute Myocarditis (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Cardiol Therapeutics Inc. | Active, not recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Inflammation • IL10 • IL1B • IL6 • TNFA

Impact of CardiolRxTM on Recurrent Pericarditis (clinicaltrials.gov) - P1 | N=25 | Not yet recruiting | Sponsor: Cardiol Therapeutics Inc.

New P1 trial • Cardiovascular • Pain • CRP

Impact of CardiolRx on Myocardial Recovery in Acute Myocarditis (clinicaltrials.gov) - P2 | N=100 | Active, not recruiting | Sponsor: Cardiol Therapeutics Inc. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Apr 2023 ➔ Jun 2025 | Trial primary completion date: Apr 2023 ➔ Dec 2024

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Inflammation • IL10 • IL1B • IL6 • TNFA

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors (clinicaltrials.gov) - P2/3 | N=422 | Recruiting | Sponsor: Cardiol Therapeutics Inc. | Trial completion date: Dec 2022 ➔ Aug 2023 | Trial primary completion date: Nov 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date • Cardiovascular • Infectious Disease • Novel Coronavirus Disease

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors (clinicaltrials.gov) - P2/3 | N=422 | Recruiting | Sponsor: Cardiol Therapeutics Inc. | Trial completion date: Apr 2022 ➔ Dec 2022 | Trial primary completion date: Mar 2022 ➔ Nov 2022

Trial completion date • Trial primary completion date • Cardiovascular • Infectious Disease • Novel Coronavirus Disease

Impact of CardiolRx on Myocardial Recovery in Acute Myocarditis (clinicaltrials.gov) - P2 | N=100 | Not yet recruiting | Sponsor: Cardiol Therapeutics Inc. | Initiation date: Jan 2022 ➔ Apr 2022

Trial initiation date • Cardiovascular • Inflammation • IL10 • IL1B • IL6 • TNFA

Impact of CardiolRx on Myocardial Recovery in Acute Myocarditis (clinicaltrials.gov) - P2; N=100; Not yet recruiting; Sponsor: Cardiol Therapeutics Inc.

Clinical • New P2 trial • Cardiovascular • Inflammation • IL10 • IL1B • IL6 • TNFA